Cure8 research brief
Researchers used genetics plus single-cell sequencing and ELISA to prioritize plasma protein ratios that may causally relate to ulcerative colitis. If validated in larger studies, such biomarkers could help with diagnosis or understanding disease biology.
Researchers and clinicians interested in UC biomarkers and disease mechanisms; adult patients who follow advances in UC diagnostics and research-minded patients.
This study used Mendelian randomization across thousands of plasma protein ratios and followed up with single-cell RNA sequencing and ELISA testing to identify candidate causal biomarkers for ulcerative colitis (UC).
The authors highlight a consistent signal for the DLL1/TGFBR2 plasma protein ratio: MR analyses implicated it as causally associated with UC risk, single-cell data showed higher DLL1/TGFBR2 in UC versus controls, and ELISA validation in 26 patient-control pairs confirmed elevation in UC.
Other protein ratios (for example CCT5/DCTN1 and BCR/DCTN1) had mixed or null validation results across methods.
These results point to DLL1/TGFBR2 as a potential diagnostic or mechanistic biomarker that may warrant further study, but this report is an initial discovery/validation using genetic instruments, sequencing, and small-sample ELISA rather than a clinical diagnostic test.
Keep reading or talk with your clinician before drawing clinical conclusions from biomarker research.
This article reports an abstract-level multi-omics study (Mendelian randomization, single-cell sequencing, ELISA) with modest ELISA sample size (26 pairs). Findings are preliminary and focused on biomarker discovery and causal inference rather than proven clinical tests.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: Conflict of interest: The authors state no conflict of interest.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Identifying an RNF213-marked Treg subset may help researchers understand immune mechanisms active in UC and could lead to new biomarker or therapeutic targets in the future.
If validated, a blood test for cytotoxic CD4+ T cells at diagnosis could help predict who is less likely to respond to anti‑TNF drugs, potentially allowing earlier selection of alternative therapies for some children...
Identifies macrophage-linked genes (CCL3, CCL4, JUNB) that are strongly upregulated in ulcerative colitis and may help explain immune-cell remodeling in the colon. These genes could serve as biomarkers or starting points...
